Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 24. Отображено 24.
18-07-2017 дата публикации

Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers

Номер: US0009708393B2
Автор: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez, RUSSO ANDREW F, KAISER ERIC A, RECOBER ANA, KUBURAS ADISA, RADDANT ANN C, KOVACEVICH BRIAN ROBERT, LATHAM JOHN A, SMITH JEFFREY T L, GARCIA-MARTINEZ LEON F, Russo Andrew F., Kaiser Eric A., Recober Ana, Kuburas Adisa, Raddant Ann C., Kovacevich Brian Robert, Latham John A., Smith Jeffrey T. L., Garcia-Martinez Leon F.
Принадлежит: ALDERBIO HOLDINGS LLC, RUSSO ANDREW F, KAISER ERIC A, RECOBER ANA, KUBURAS ADISA, RADDANT ANN C, KOVACEVICH BRIAN ROBERT, LATHAM JOHN A, SMITH JEFFREY T L, GARCIA-MARTINEZ LEON F, Russo Andrew F., Kaiser Eric A., Recober Ana, Kuburas Adisa, Raddant Ann C., Kovacevich Brian Robert, Latham John A., Smith Jeffrey T. L., Garcia-Martinez Leon F.

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like.

Подробнее
Номер записи: 1
02-01-2018 дата публикации

Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels

Номер: US0009855332B2
Автор: Andrew F. Russo, Eric A. Kaiser, Ana Recober, Adisa Kuburas, Ann C. Raddant, Brian Robert Kovacevich, John A. Latham, Jeffrey T. L. Smith, Leon F. Garcia-Martinez, RUSSO ANDREW F, KAISER ERIC A, RECOBER ANA, KUBURAS ADISA, RADDANT ANN C, KOVACEVICH BRIAN ROBERT, LATHAM JOHN A, SMITH JEFFREY T L, GARCIA-MARTINEZ LEON F, Russo Andrew F., Kaiser Eric A., Recober Ana, Kuburas Adisa, Raddant Ann C., Kovacevich Brian Robert, Latham John A., Smith Jeffrey T. L., Garcia-Martinez Leon F.
Принадлежит: ALDERBIO HOLDINGS LLC, RUSSO ANDREW F, KAISER ERIC A, RECOBER ANA, KUBURAS ADISA, RADDANT ANN C, KOVACEVICH BRIAN ROBERT, LATHAM JOHN A, SMITH JEFFREY T L, GARCIA-MARTINEZ LEON F, Russo Andrew F., Kaiser Eric A., Recober Ana, Kuburas Adisa, Raddant Ann C., Kovacevich Brian Robert, Latham John A., Smith Jeffrey T. L., Garcia-Martinez Leon F.

The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof.

Подробнее
Номер записи: 2
22-11-2012 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS

Номер: US20120294802A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian Robert, Kuburas Adisa, Latham John A., Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. 1). A method of inhibiting photophobia or light aversion or precluding the onset of photophobia or photoaversion in a subject in need thereof comprising administering an effective amount of an anti-CGRP antibody or antibody fragment , anti-CGRP receptor antibody or fragment , or a polypeptide comprising a fragment of CGRP or a CGRP receptor , wherein the antibody or antibody fragment or fragment of CGRP or CGRP receptor reduces or prevents CGRP-associated photophobia or light aversion.2). The method of wherein the administered molecule comprises an anti-CGRP antibody or antibody fragment.3). The method of or wherein the treated subject suffers from one or more of the following: chronic migraine claim 1 , hemiplegic migraines claim 1 , cluster headaches claim 1 , migrainous neuralgia claim 1 , chronic headaches claim 1 , tension headaches claim 1 , general headaches claim 1 , hot flashes claim 1 , chronic paroxysomal hemicrania claim 1 , secondary headaches due to an underlying structural problem in the head or neck claim 1 , cranial neuralgia claim 1 , sinus headaches claim 1 , allergy-induced headaches claim 1 , menopausal migraine claim 1 , menstrual migraine claim 1 , or headache claim 1 , headache-free migraine claim 1 , abdominal migraine claim 1 , or other migraine condition.4). The method of or wherein the subject has a ocular disorder associated with photophobia selected from Achromatopsia claim 1 , Aniridia claim 1 , photophobia caused by an Anticholinergic drug claim 1 , Aphakia (absence of the lens of the eye) claim 1 , Buphthalmos (abnormally narrow angle between the cornea and ...

Подробнее
Номер записи: 3
22-11-2012 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS

Номер: US20120294822A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian Robert, Kuburas Adisa, Latham John A., Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof. 1. A method of inhibiting , preventing or treating diarrhea or dysentery and/or maintaining appropriate electrolyte and fluid levels in the colon of a subject or in need thereof , comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment.2. The method of claim 1 , wherein the diarrhea or dysentery is associated with increased CGRP.3. The method of claim 1 , wherein the diarrhea is acute diarrhea or chronic diarrhea.4. The method of claim 1 , wherein the diarrhea comprises osmotic diarrhea claim 1 , secretory diarrhea claim 1 , motility diarrhea claim 1 , exudative diarrhea claim 1 , and/or inflammatory diarrhea.5. The method of claim 1 , wherein diarrhea is caused by a chronic or acute condition selected from a functional bowel disorder claim 1 , irritable bowel syndrome claim 1 , coeliac disease claim 1 , pancreatic disease claim 1 , pancreatitis claim 1 , type 1 or type 2 diabetes claim 1 , cystic fibrosis claim 1 , Crohn's disease claim 1 , diabetic neuropathy claim 1 , menstruation claim 1 , hyperthyroidism claim 1 , hormone imbalance claim 1 , enteritis claim 1 , an inflammatory bowel disease claim 1 , microscopic colitis claim 1 , ischemic bowel disease claim 1 , ulcerative colitis claim 1 , mucositis claim 1 , or tuberculosis.6. The method of claim 1 , wherein the ...

Подробнее
Номер записи: 4
14-06-2018 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS

Номер: US20180161434A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian R., Kuburas Adisa, Latham John, Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof. 177-. (canceled)78. A method of inhibiting , preventing or treating diarrhea in a subject comprising elevated levels of CGRP , wherein said elevated CGRP levels are associated with an acute condition comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment , wherein the anti-CGRP antibody or antibody fragment comprises the variable light (V) CDR1 , CDR2 , and CDR3 of SEQ ID NOs:55 , 56 and 57 , respectively , and the variable heavy (V) CDR1 , CDR2 , and CDR3 of SEQ ID NOs:58 , 59 and 60 , respectively.79. A method of inhibiting , preventing or treating diarrhea in a subject comprising elevated levels of CGRP , wherein said elevated CGRP levels are associated with a chronic condition comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment , wherein the anti-CGRP antibody or antibody fragment comprises the variable light (V) CDR1 , CDR2 , and CDR3 of SEQ ID NOs:55 , 56 and 57 , respectively , and the variable heavy (V) CDR1 , CDR2 , and CDR3 of SEQ ID NOs:58 , 59 and 60 , respectively.80. The method of claim 78 , wherein the anti-CGRP antibody or anti-CGRP antibody fragment comprises a variable light (V) chain polypeptide that possesses at least 90% sequence identity to the polypeptide of SEQ ID NO:31 claim 78 , 41 or 51.81. The ...

Подробнее
Номер записи: 5
08-08-2019 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO TREAT DIARRHEA IN SUBJECTS WITH DISEASES OR TREATMENTS THAT RESULT IN ELEVATED CGRP LEVELS

Номер: US20190240331A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian R., Kuburas Adisa, Latham John, Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods for treating diarrhea, both chronic or acute forms, by the administration of a therapeutically or prophylactically effective amount of antibodies and fragments thereof having binding specificity for CGRP. In particular the methods prevent or reduce diarrhea in conditions or treatments resulting in elevated CGRP levels, e.g., in the GI tract (colon) that are associated with diarrhea and/or improper electrolyte and fluid excretion from the bowel or urinary system. More specifically, this invention relates to treatments using the anti-CGRP antibodies and fragments described herein, and binding fragments thereof. 177-. (canceled)78. A method of inhibiting , preventing or treating diarrhea in a subject comprising elevated levels of CGRP , wherein said elevated CGRP levels are associated with an acute condition comprising administering an effective amount of an anti-CGRP antibody or anti-CGRP antibody fragment , wherein the anti-CGRP antibody or antibody fragment is selected from the following:{'sub': L', 'H, '(i) one which comprises the variable light (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:5, 6 and 7, respectively, and the variable heavy (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:8, 9 and 10, respectively;'}{'sub': L', 'H, '(ii) one which comprises the variable light (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:15, 16 and 17, respectively, and the variable heavy (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:18, 19 and 20, respectively;'}{'sub': L', 'H, '(iii) one which comprises the variable light (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:25, 26 and 27, respectively, and the variable heavy (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:28, 29 and 30, respectively;'}{'sub': L', 'H, '(iv) one which comprises the variable light (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:35, 36 and 37, respectively, and the variable heavy (V) CDR1, CDR2, and CDR3 of SEQ ID NOs:38, 39 and 40, respectively;'}{'sub': L', 'H, '(v) one which comprises the variable light (V) CDR1, ...

Подробнее
Номер записи: 6
05-09-2019 дата публикации

USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA

Номер: US20190270807A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Katherine Lee, Karasek Charlie, Kuburas Adisa, Latham John A., Loomis Maria-Cristina, MASON Bianca, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Russo Andrew F., Scalley-Kim Michelle, Smith Jeffrey T.L., SOWERS Levi P., Stewart Erica
Принадлежит:

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof 1. A method of screening for an antibody or antigen binding fragment suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion , or precluding the onset of PACAP-associated photophobia or light aversion , in a subject in need thereof , which comprises:(i) providing at least one first test subject and at least one second test subject;(ii) administering PACAP to the at least one first test subject and the at least one second test subject;(iii) further administering to the at least one first test subject one or more anti-PACAP antibodies, anti-Pituitary Adenylate Cyclase Activating Polypeptide type 1 Receptor (PAC1-R) antibodies, anti-vasoactive intestinal peptide receptor type 1 (VPAC1-R) antibodies, or anti-vasoactive intestinal peptide receptor type 2 (VPAC2-R) antibodies, or an antigen binding fragment of any of the foregoing;(iv) comparing the response of the at least one first test subject and at least one second test subject to light; and(v) based on this comparison, identifying one or more antibodies or antigen binding fragments thereof that yield a decreased light aversion or decreased photophobia in the at least one first test subject as compared with the at least one second test subject, thereby identifying an antibody or antigen binding fragment suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a subject in need thereof, with the proviso that none of said anti-PACAP ...

Подробнее
Номер записи: 7
30-11-2017 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS

Номер: US20170342141A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian R., Kuburas Adisa, Latham John, Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. 174-. (canceled)75. A method of inhibiting Calcitonin Gene Related Peptide (CGRP)-associated photophobia or light aversion or precluding the onset of CGRP-associated photophobia or photoaversion associated with a migrainous condition or cluster headache condition in a subject comprising administering an effective amount of an anti-CGRP antibody or antibody fragment which comprises the same six CDR sequences as an antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 and Ab14.76. The method of claim 75 , wherein said anti-CGRP antibody or antibody fragment is human claim 75 , humanized claim 75 , or chimeric.77. The method of claim 75 , wherein said anti-CGRP antibody fragment is an scFv claim 75 , camelbody claim 75 , nanobody claim 75 , IgNAR claim 75 , Fab claim 75 , Fab′ claim 75 , or F(ab)fragment.78. The method of claim 75 , wherein said CGRP-associated photophobia is the result of a migraine or another headache condition associated with photophobia.79. The method of claim 78 , wherein said CGRP-associated photophobia is caused by a condition selected from the group consisting of chronic migraine claim 78 , hemiplegic migraine claim 78 , cluster headache claim 78 , migrainous neuralgia claim 78 , menopausal migraine claim 78 , menstrual migraine claim 78 , headache-free migraine claim 78 , and abdominal migraine.80. The method of claim 75 , wherein the treated subject is a chronic migraine or cluster headache sufferer.81. The method of claim 76 , wherein said anti-CGRP antibody or antibody fragment is humanized.82. The ...

Подробнее
Номер записи: 8
15-12-2016 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US20160361441A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Lee HENDRICKS, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals Inc, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 9
29-12-2016 дата публикации

USE OF ANTI-PACAP ANTIBODIES AND ANTIGEN BINDING FRAGMENTS THEREOF FOR TREATMENT, PREVENTION, OR INHIBITION OF PHOTOPHOBIA

Номер: US20160376363A1
Автор: Allison Daniel S., Billgren Jens J., Dutzar Benjamin H., Fan Pei, Garcia-Martinez Leon F., HENDRICKS Lee, Karasek Charlie, Kuburas Adisa, Latham John A., Loomis Maria-Cristina, MASON Bianca, Mulligan Jenny, Ojala Ethan W., Rubin Vanessa Lisbeth, Russo Andrew F., Scalley-Kim Michelle, Smith Jeffrey T.L., SOWERS Levi P., Stewart Erica
Принадлежит:

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof. 1. A method of screening for an antibody or antigen binding fragment suitable for use in treating or preventing Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-associated photophobia or light aversion , or precluding the onset of PACAP-associated photophobia or light aversion , in a subject in need thereof , which comprises:(i) providing at least one first test subject and at least one second test subject;(ii) administering PACAP to the at least one first test subject and the at least one second test subject;(iii) further administering to the at least one first test subject one or more anti-PACAP antibodies, anti-Pituitary Adenylate Cyclase Activating Polypeptide type 1 Receptor (PAC1-R) antibodies, anti-vasoactive intestinal peptide receptor type 1 (VPAC1-R) antibodies, or anti-vasoactive intestinal peptide receptor type 2 (VPAC2-R) antibodies, or an antigen binding fragment of any of the foregoing;(iv) comparing the response of the at least one first test subject and at least one second test subject to light; and(v) based on this comparison, identifying one or more antibodies or antigen binding fragments thereof that yield a decreased light aversion or decreased photophobia in the at least one first test subject as compared with the at least one second test subject, thereby identifying an antibody or antigen binding fragment suitable for use in treating or preventing PACAP-associated photophobia or light aversion, or precluding the onset of PACAP-associated photophobia or light aversion in a subject in need thereof.2. A method of screening for an antibody or antigen ...

Подробнее
Номер записи: 10
05-12-2019 дата публикации

USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS

Номер: US20190367590A1
Автор: Garcia-Martinez Leon F., Kaiser Eric A., Kovacevich Brian R., Kuburas Adisa, Latham John, Raddant Ann C., Recober Ana, Russo Andrew F., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. 174-. (canceled)75. A method of inhibiting Calcitonin Gene Related Peptide (CGRP)-associated photophobia or light aversion or precluding the onset of CGRP-associated photophobia or photoaversion associated with a migrainous condition or cluster headache condition in a subject comprising administering an effective amount of an anti-CGRP antibody or antibody fragment which comprises the same six CDR sequences as an antibody selected from the group consisting of Ab1 , Ab2 , Ab3 , Ab4 , Ab5 , Ab7 , Ab8 , Ab9 , Ab10 , Ab11 , Ab12 , Ab13 and Ab14.76. The method of claim 75 , wherein said anti-CGRP antibody or antibody fragment is human claim 75 , humanized claim 75 , or chimeric.77. The method of claim 75 , wherein said anti-CGRP antibody fragment is an scFv claim 75 , camelbody claim 75 , nanobody claim 75 , IgNAR claim 75 , Fab claim 75 , Fab′ claim 75 , or F(ab)fragment.78. The method of claim 75 , wherein said CGRP-associated photophobia is the result of a migraine or another headache condition associated with photophobia.79. The method of claim 78 , wherein said CGRP-associated photophobia is caused by a condition selected from the group consisting of chronic migraine claim 78 , hemiplegic migraine claim 78 , cluster headache claim 78 , migrainous neuralgia claim 78 , menopausal migraine claim 78 , menstrual migraine claim 78 , headache-free migraine claim 78 , and abdominal migraine.80. The method of claim 75 , wherein the treated subject is a chronic migraine or cluster headache sufferer.81. The method of claim 76 , wherein said anti-CGRP antibody or antibody fragment is humanized.82. The ...

Подробнее
Номер записи: 11
26-08-2022 дата публикации

Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea

Номер: NZ717704A
Автор: Adisa Kuburas, Ana Recober, Andrew F Russo, Ann C Raddant, Brian Robert KOVACEVICH, Eric A Kaiser, Jeffrey T L Smith, John A Latham, Leon F Garcia-Martinez
Принадлежит: H Lundbeck AS, The Univ Of Iowa Research Foundation

Disclosed the use of an anti-CGRP antibody or anti-CGRP antibody fragment or an anti-CGRP (CGRP-R) receptor antibody or an anti-CGRP-R antibody fragment in the manufacture of a medicament for inhibiting, preventing or treating diarrhea or dysentery and/or maintaining appropriate electrolyte and fluid levels in the colon of a subject having diarrhea or dysentery.

Подробнее
Номер записи: 12
29-11-2012 дата публикации

Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers

Номер: WO2012162257A2
Автор: Adisa Kuburas, Ana Recober, Andrew F. Russo, Ann C. RADDANT, Brian Robert KOVACEVICH, Eric A. KAISER, Jeffrey T.L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC, THE UNIVERSITY OF IOWA RESEARCH FOUNDATION

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the V H, V L and CDR polypeptides described herein, and the polynucleotides encoding them.

Подробнее
Номер записи: 13
21-02-2018 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: EP3283169A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan Wayne Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John Latham, Katherine Lee HENDRIX, Leon Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals Inc, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 14
10-05-2022 дата публикации

Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light a version in subjects in need thereof, especially migraine sufferers

Номер: US11325967B2
Автор: Adisa Kuburas, Ana Recober, Andrew F. Russo, Ann C. RADDANT, Brian R. Kovacevich, Eric A. KAISER, Jeffrey T. L. Smith, John Latham, Leon F. Garcia-Martinez
Принадлежит: H Lundbeck AS, University of Iowa Research Foundation UIRF

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the V H , V L and CDR polypeptides described herein, and the polynucleotides encoding them.

Подробнее
Номер записи: 15
01-03-2019 дата публикации

Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers

Номер: NZ717700B2
Автор: Adisa Kuburas, Ana Recober, Andrew F Russo, Ann C Raddant, Brian Robert KOVACEVICH, Eric A Kaiser, Jeffrey Tl Smith, John A Latham, Leon F Garciamartinez, Martinez Leon F Garcia
Принадлежит: H LUNDBECK A/S

Disclosed is a method of assessing the potential in vivo efficacy of a candidate anti-CGRP antibody or anti-CGRP antibody fragment, anti-CGRP receptor antibody or anti-CGRP receptor antibody fragment, or a polypeptide comprising a fragment of CGRP or CGRP receptor for treating photophobia or light aversion, comprising determining whether the candidate inhibits light aversive behaviour in a nestin/Ramp1 rodent administered CGRP compared to a rodent administered CGRP in the absence of the candidate. version, comprising determining whether the candidate inhibits light aversive behaviour in a nestin/Ramp1 rodent administered CGRP compared to a rodent administered CGRP in the absence of the candidate.

Подробнее
Номер записи: 16
15-06-2017 дата публикации

Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers

Номер: AU2012258980A8
Автор: Adisa Kuburas, Ana Recober, Andrew F. Russo, Ann C. RADDANT, Brian Robert KOVACEVICH, Eric A. KAISER, Jeffrey T.L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC, Univ Of Iowa Res Found, University of Iowa Research Foundation UIRF

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the V

Подробнее
Номер записи: 17
20-10-2016 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: WO2016168757A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan Wayne Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John Latham, Lee HENDRICKS, Leon Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals, Inc., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 18
30-12-2013 дата публикации

Use of anti-cgrp or anti-cgrp-r antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea

Номер: SG194974A1
Автор: Adisa Kuburas, Ana Recober, Andrew F Russo, Ann C Raddant, Brian Robert KOVACEVICH, Eric A Kaiser, Jeffrey T L Smith, John A Latham, Leon F Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC, Univ Iowa Res Found

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)(19) World Intellectual Property OrganizationInternational Bureau(43) International Publication Date 29 November 2012 (29.11.2012) WIPO I PCT (10) International Publication NumberWO 2012/162253 A2 (51) International Patent Classification:A61K 39/395 (2006.01) A61K 31/7088 (2006.01)A61K 48/00 (2006.01) A61P 1/12 (2006.01)A61K 38/16 (2006.01)International Application Number: PCT/U52012/038869International Filing Date: 21 May 2012 (21.05.2012)Filing Language: EnglishPublication Language: English(30) Priority Data:61/488,660 20 May 2011 (20.05.2011) US61/496,873 14 June 2011 (14.06.2011) USApplicants (fo- all designated States except US): ALDER BIO HOLDINGS LLC [US/US]; 101 Convention Center Dr., Ste. 850, Las Vegas, Nevada 89109 (US). THE UNI VERSITY OF IOWA RESEARCH FOUNDATION [US/US]; 2660 University Capitol Center, Iowa City, Iowa 52242-5500 (US).Inventors; and(75) Inventors/Applicants (fo- US only): RUSSO, Andrew F. [US/US]; 1762 Winston Dr., Iowa City, Iowa 52245 (US). KAISER, Eric A. [US/US]; 4924 E. Court St., Iowa City, Iowa 52245 (US). RECOBER, Ana [US/US]; 15 Cherry Ln. NE, Iowa City, Iowa 52240 (US). KUBURAS, Adisa [US/US]; 1480 Harvest St., North Liberty, Iowa 52317 (US). RADDANT, Ann C. [US/US]; 460 Samoa Dr., Iowa City, Iowa 52246 (US). KOVACEVICH, Brian Robert [US/US]; 13916 233rd St. SE, Snohomish, Washington 98296 (US). LATHAM, John A. [US/US]; 2409 10th Ave. NW, Seattle, Washington 98119 (US). SMITH, Jef frey T.L. [GB/US]; 10270 NE 12th St., Apt. F307, Bel levue, Washington 98004 (US). GARCIA-MARTINEZ, Leon F. [US/US]; 4926 214th St. SE, Woodinville, Wash ington 98072 (US). (74) Agent: TESKIN, Robin L.; Bunton & Williams LLP, 2200 Pennsylvania Ave. NW, Washington, District of Columbia 20037 (US).(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, ...

Подробнее
Номер записи: 19
21-10-2021 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US20210324068A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 20
29-11-2012 дата публикации

Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers

Номер: CA3048709A1
Автор: Adisa Kuburas, Ana Recober, Andrew F. Russo, Ann C. RADDANT, Brian Robert KOVACEVICH, Eric A. KAISER, Jeffrey T.L. Smith, John A. Latham, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC, University of Iowa Research Foundation UIRF

The present invention is directed to methods of inhibiting or preventing photophobia in subjects in need thereof using anti-CGRP antibodies or antibody fragments that inhibit photophobia, especially CGRP-associated photophobia. These antibodies and fragments are useful in treating different disorders associated with photophobia such as migraine, cluster headaches and the like. The present invention also provides assays using transgenic Nestin/Ramp 1 rodents, utilizing a CGRP model light aversive behavior model for identifying therapeutically effective anti-CGRP antibodies and fragments thereof having binding specificity for CGRP which inhibit or prevent photophobia in subjects in need thereof. The present invention is specifically directed to methods for identifying therapeutically effective antibodies and fragments thereof having binding specificity for CGRP that may be used to treat CGRP associated disorders such as migraine. Specifically, this invention relates to assays and therapies using the antibodies described herein to inhibit or prevent photophobia, and binding fragments thereof, comprising the sequences of the VH, VL and CDR polypeptides described herein, and the polynucleotides encoding them.

Подробнее
Номер записи: 21
20-10-2016 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: WO2016168760A1
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan Wayne Ojala, Jeffrey T.L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John Latham, Lee HENDRICKS, Leon Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: Alder Biopharmaceuticals, Inc., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 22
24-11-2020 дата публикации

Use of anti-pacap antibodies and antigen binding fragments thereof for treatment, prevention, or inhibition of photophobia

Номер: US10844116B2
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 23
28-05-2024 дата публикации

Screening method for identifying anti-PACAP antibodies or antibody fragments suitable for use in treating or preventing PACAP-associated photophobia or light aversion

Номер: US11993648B2
Автор: Adisa Kuburas, Andrew F. Russo, Benjamin H. Dutzar, Bianca MASON, Charlie KARASEK, Daniel S. Allison, Erica STEWART, Ethan W. Ojala, Jeffrey T. L. Smith, Jenny MULLIGAN, Jens J. BILLGREN, John A. Latham, Katherine Lee HENDRIX, Leon F. Garcia-Martinez, Levi P. Sowers, Maria-Cristina Loomis, Michelle Scalley-Kim, Pei Fan, Vanessa Lisbeth RUBIN
Принадлежит: H Lundbeck AS, University of Iowa Research Foundation UIRF

This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

Подробнее
Номер записи: 24